Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
用于烷化剂氟达拉滨(fludarabine)治疗失败的B细胞性慢性淋巴细胞白血病患者;亦可用于复发缓解型多发性硬化症治疗。
University of Miami School of Medicine, Miami, Florida, United States
University of California, San Francisco, San Francisco, California, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States
Cancer Center of Kansas-Independence, Independence, Kansas, United States
Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.